Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

We expect Lilly to continue to grow faster than the market, and model 60% 2025 Lilly GLP-1 sales growth. Lilly gained 5 points in US prescription share in 2024, and Zepbound’s 56% share of new ...

At the same time, Bessent's emphasis on expanding energy supply omits other significant inputs for the 10-year. "Concrete ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

Honeywell is the worst Dow Jones stock Thursday as the industrial conglomerate's weak outlook offsets news that it is ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Eli Lilly & Co (LLY – Research Report).

B, consensus $58.91B. The company said, “The company anticipates 2025 revenue to be between $58.0 billion and $61.0 ...